Laval, QC, Canada - February 29, 2016, Laval, QC, Canada - Valeant Pharmaceuticals International, Inc. announced that J. Michael Pearson returns as Valeant's chief executive officer, effective immediately.
Article continues below
Mr. Pearson returns to the position following his recovery from severe pneumonia and other complications.
Howard B. Schiller, Valeant's interim chief executive officer, will transition out of his current duties but will continue as a member of Valeant's Board of Directors.
Robert A. Ingram has been appointed Chairman of the Board as the Company has separated the roles of Chairman and Chief Executive Officer.
Mr. Ingram has been serving on the Board of the Company since September 2010, was the Lead Director from September 2010 to December 2010, was the Chairman of the Board from December 2010 to March 2011 and is now our Lead Director. In January 2016 he was named interim Chairman of the Board.
Since January 2007, Mr. Ingram has been a general partner at Hatteras Venture Partners, a venture capital firm with a focus on biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. Since January 2010, he has served as a special advisor to the Chief Executive Officer of GlaxoSmithKline.
He served as Vice Chairman Pharmaceuticals of GSK from 2002 through 2009 and Chief Operating Officer and President of Pharmaceutical Operations, CEO of Glaxo Wellcome plc from October 1997 to December 2000 and chairman of the board of Glaxo Wellcome Inc., Glaxo Wellcome plc’s U.S. subsidiary, from January 1999 to December 2000.
Mr. Ingram was President and CEO of Glaxo Wellcome Inc. from October 1997 to January 1999. He is also a member of the Board of Advisors for the H. Lee Moffitt Cancer Center and Research Triangle Institute, as well as Chairman of the Board, Research Triangle Foundation of North Carolina and Glaxo North Carolina Foundation.
Mr. Ingram currently serves on the boards of Regeneron Pharmaceuticals, Inc. (member of Compensation Committee), Edwards Life Sciences Corporation (member of compensation committee) and CREE, Inc. (lead director, member of compensation committee and governance and nominations committee). ■